Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;75(1):60-9.
doi: 10.1002/pros.22892. Epub 2014 Oct 4.

Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence

John P Gerstenberger  1 , Scott R Bauer, Erin L Van Blarigan, Eduardo Sosa, Xiaoling Song, John S Witte, Peter R Carroll, June M Chan
Affiliations

Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence

John P Gerstenberger et al. Prostate. 2015 Jan.

Abstract

Background: Observational studies suggest an inverse association between selenium and risk of prostate cancer. However, randomized controlled trials of selenium supplementation have reported conflicting results. Thus, we examined plasma selenium and selenium-related genes in relation to risk of high-grade prostate cancer and prostate cancer recurrence among men initially diagnosed with non-metastatic disease.

Methods: We measured plasma selenium and genotyped 73 single nucleotide polymorphisms in TXNRD1, TXNRD2, GPX1, GPX3, GPX4, SEP15, SEPP1, SELENBP1, OGG1, and CAT among 568 men with non-metastatic prostate cancer who underwent radical prostatectomy. We examined associations between plasma selenium, genotypes, and risk of high-grade prostate cancer (Gleason grade ≥8 or 7 with primary score ≥4; n = 111) using logistic regression, and risk of prostate cancer recurrence (61 events; 3.8 y median follow-up) using Cox proportional hazards regression.

Results: Plasma selenium was not associated with risk of high-grade prostate cancer or prostate cancer recurrence. Less common alleles of rs11913319 in TXNRD2 and rs125701 in OGG1 were associated with an increased risk of high-grade prostate cancer. We observed associations between the risk of prostate cancer recurrence and multiple SNPs in TXNRD1, TXNRD2, GPX3, and SEP15. These associations were no longer statistically significant after adjustment for multiple comparisons.

Conclusions: Among men with non-metastatic prostate cancer, there is suggestive evidence that genetic variation in selenoproteins and related antioxidant enzymes may be associated with risk of high-grade disease at diagnosis and prostate cancer recurrence.

Keywords: Gleason grade; genetic polymorphisms; selenium.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST: None.

Figures

Figure 1
Figure 1
Plot of log-transformed p-values for an additive model of association between genotype at each of 73 SNPs in candidate antioxidant and selenoprotein genes and the relative risk of high-grade prostate cancer at diagnosis. The horizontal line indicates a chosen significance threshold of P=.05, and colors indicate gene as shown.
Figure 2
Figure 2
Plot of log-transformed p-values for an additive model of association between genotype at each of 73 SNPs in candidate antioxidant and selenoprotein genes and the relative risk of prostate cancer recurrence. The horizontal line indicates a chosen significance threshold of P=.05, and colors indicate gene as shown.
See this image and copyright information in PMC

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA A Cancer Journal for Clinicians. 2014 Jan 7;64(1):9–29. - PubMed
    1. Hurst R, Hooper L, Norat T, Lau R, Aune D, Greenwood DC, et al. Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr. 2012 Jun 20;96(1):111–122. - PubMed
    1. Etminan M, FitzGerald JM, Gleave M, Chambers K. Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control. 2005 Nov;16(9):1125–1131. - PubMed
    1. Brinkman M, Reulen RC, Kellen E, Buntinx F, Zeegers MP. Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer. 2006 Oct;42(15):2463–2471. - PubMed
    1. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MPA, Horneber M. Selenium for preventing cancer. Cochrane Database Syst Rev. 2011;(5):CD005195. - PMC - PubMed

Publication types